Possibilities and prospects for glucocorticoid withdrawal in systemic lupus erythematosus
The efficiency of glucocorticoid (GC) therapy for systemic lupus erythematosus (SLE) is beyond question and is confirmed by the experience gained over many decades of their use. However, there are many problems with prolonged GC use, even in its low and medium doses. In particular, the development o...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2020-03-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/986 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849242057782067200 |
|---|---|
| author | S. K. Solovyev E. A. Aseeva E. L. Nasonov A. M. Lila G. M. Koilubaeva |
| author_facet | S. K. Solovyev E. A. Aseeva E. L. Nasonov A. M. Lila G. M. Koilubaeva |
| author_sort | S. K. Solovyev |
| collection | DOAJ |
| description | The efficiency of glucocorticoid (GC) therapy for systemic lupus erythematosus (SLE) is beyond question and is confirmed by the experience gained over many decades of their use. However, there are many problems with prolonged GC use, even in its low and medium doses. In particular, the development of GC-associated irreversible organ damages significantly worsens prognosis and causes a decrease in quality of life and social adaptation and a substantial increase in treatment costs. On the other hand, the current capabilities of early diagnosis, pathogenetic therapy, and monitoring in many patients with SLE allow for maintaining low disease activity and remission, the conditions in which the feasibility of further GC treatment can and should be decided. The paper gives the data available in the literature and the authors’ own studies on the possibility and prospects of GC withdrawal in SLE patients in a stage of low disease activity and remission. |
| format | Article |
| id | doaj-art-7926753d74cc4daebff91e5d836e2ea2 |
| institution | Kabale University |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2020-03-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-7926753d74cc4daebff91e5d836e2ea22025-08-20T03:59:56ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2020-03-0114161110.14412/1996-7012-2020-1-6-112229Possibilities and prospects for glucocorticoid withdrawal in systemic lupus erythematosusS. K. Solovyev0E. A. Aseeva1E. L. Nasonov2A. M. Lila3G. M. Koilubaeva4V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaAcademician Mirsaid Mirrakhimov National Center of Cardiology and TherapyThe efficiency of glucocorticoid (GC) therapy for systemic lupus erythematosus (SLE) is beyond question and is confirmed by the experience gained over many decades of their use. However, there are many problems with prolonged GC use, even in its low and medium doses. In particular, the development of GC-associated irreversible organ damages significantly worsens prognosis and causes a decrease in quality of life and social adaptation and a substantial increase in treatment costs. On the other hand, the current capabilities of early diagnosis, pathogenetic therapy, and monitoring in many patients with SLE allow for maintaining low disease activity and remission, the conditions in which the feasibility of further GC treatment can and should be decided. The paper gives the data available in the literature and the authors’ own studies on the possibility and prospects of GC withdrawal in SLE patients in a stage of low disease activity and remission.https://mrj.ima-press.net/mrj/article/view/986systemic lupus erythematosusglucocorticoidsirreversible organ damagesbiological agents |
| spellingShingle | S. K. Solovyev E. A. Aseeva E. L. Nasonov A. M. Lila G. M. Koilubaeva Possibilities and prospects for glucocorticoid withdrawal in systemic lupus erythematosus Современная ревматология systemic lupus erythematosus glucocorticoids irreversible organ damages biological agents |
| title | Possibilities and prospects for glucocorticoid withdrawal in systemic lupus erythematosus |
| title_full | Possibilities and prospects for glucocorticoid withdrawal in systemic lupus erythematosus |
| title_fullStr | Possibilities and prospects for glucocorticoid withdrawal in systemic lupus erythematosus |
| title_full_unstemmed | Possibilities and prospects for glucocorticoid withdrawal in systemic lupus erythematosus |
| title_short | Possibilities and prospects for glucocorticoid withdrawal in systemic lupus erythematosus |
| title_sort | possibilities and prospects for glucocorticoid withdrawal in systemic lupus erythematosus |
| topic | systemic lupus erythematosus glucocorticoids irreversible organ damages biological agents |
| url | https://mrj.ima-press.net/mrj/article/view/986 |
| work_keys_str_mv | AT sksolovyev possibilitiesandprospectsforglucocorticoidwithdrawalinsystemiclupuserythematosus AT eaaseeva possibilitiesandprospectsforglucocorticoidwithdrawalinsystemiclupuserythematosus AT elnasonov possibilitiesandprospectsforglucocorticoidwithdrawalinsystemiclupuserythematosus AT amlila possibilitiesandprospectsforglucocorticoidwithdrawalinsystemiclupuserythematosus AT gmkoilubaeva possibilitiesandprospectsforglucocorticoidwithdrawalinsystemiclupuserythematosus |